Parkinson's disease
BioArctic Doses First Parkinson's Patient in Trial of Alpha-Synuclein-Targeting Drug
Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.
Denali Therapeutics Doses First LRRK2 Parkinson's Patient in Phase IIa Trial
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Gain Therapeutics to Start Testing GCase-Targeted Drug in Patients with GBA1, Sporadic Parkinson's
Premium
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by GBA1.
Neuron23 to Launch Phase II Trial in LRRK2-Driven Parkinson's in Early 2025
The firm will test the activity of NEU-411 in patients with Parkinson's caused by LRRK2 mutations or whose disease is influenced by LRRK2 overactivity.
Alamar Biosciences, Michael J. Fox Foundation Partner on Parkinson's Research
The partners will use Alamar's NULISA proteomics platform to develop assays for identifying biomarkers linked to neuronal synuclein diseases including Parkinson's.
Oct 16, 2024
Sunbird Bio Nabs $14M in Financing
Sep 19, 2024
Aug 13, 2024
MeiraGTx Gets $30M Equity Investment From Sanofi
Mar 28, 2024
Mar 27, 2024
Dec 6, 2023